Physician profile
Parul Khator
NPI 1487840047
$6,959.41
in general payments reported to CMS, 2019-2025
28 companies · $1,859 in 2025
The $1,859 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $541 · 2021: $678 · 2022: $1,644 · 2023: $1,139 · 2024: $656 · 2025: $1,859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,564 · Entertainment: $71.35 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,564.16 |
| Entertainment | $71.35 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,665.72 | 2019-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Abbvie INC. | $1,122.27 | 2022-2025 | |
| Glaukos Corporation | $909.44 | 2020-2025 | Idosetr, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Iaccess Precision Blade |
| Allergan, INC. | $615.32 | 2019-2022 | |
| Sight Sciences, INC. | $494.99 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Sun Pharmaceutical Industries INC. | $468.27 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $266.54 | 2022-2025 | Vyzulta, Miebo, Envista Aspire Iol |
| Johnson & Johnson Surgical Vision, INC. | $171.52 | 2022-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Aerie Pharmaceuticals, INC. | $159.03 | 2019-2021 | |
| Biotissue Holdings INC. | $145.87 | 2025 | |
| Nova Eye, INC. | $123.00 | 2024-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.81 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $84.94 | 2020-2022 | |
| Oyster Point Pharma, INC. | $79.51 | 2022 | |
| Ivantis, INC | $73.07 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akorn, INC. | $71.31 | 2019 | |
| Ocular Therapeutix, INC. | $65.64 | 2024-2025 | Dextenza |
| Dompe US, INC. | $56.37 | 2019-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $56.10 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $41.01 | 2025 | Xdemvy |
| Akorn Operating Company LLC | $33.86 | 2021 | |
| Amgen INC. | $32.81 | 2024 | Tepezza |
| Rayner Intraocular Lenses Limited | $25.43 | 2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Horizon Therapeutics Plc | $21.87 | 2021 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| New World Medical,INC. | $16.80 | 2025 | Clearpath, Streamline, Via360 |
| Kala Pharmaceuticals, INC. | $16.59 | 2022 | |
| Omeros Corporation | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parul Khator listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.